• Publications
  • Influence
PROSPECTIVE STUDY
TLDR
Adjuvant therapy sparing in rectal cancer ypT0N0 had five-year disease-free and overall survival rates of 96% (95%CI: 77-99) and 100%, respectively and withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision might be safe within an experienced multidisciplinary team.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
TLDR
Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
TLDR
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
TLDR
Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
TLDR
Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
TLDR
Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months.
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
TLDR
Interestingly, the mutations identified resulted in premature chain termination or direct abrogation of histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
TLDR
Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
TLDR
It is recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily and the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT) is confirmed.
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
TLDR
The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
...
1
2
3
4
5
...